Up-Front Payments. In partial consideration for the licences granted to GSK by Genmab under this Agreement, [***] after the Closing Date and upon receipt of an invoice from Genmab, GSK shall pay, or cause to be paid to Genmab, Five Hundred Eighty One Million and Six Hundred and Forty Thousand Danish Kroners (581,640,000 DKK).
Appears in 2 contracts
Sources: Co Development and Collaboration Agreement (Genmab a/S), Co Development and Collaboration Agreement (Genmab a/S)